Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Developments and current pharmacotherapeutic recommendations for ankylosing spondylitis.

Jane Zochling1, Jürgen Braun

  • 1Rheumazentrum-Ruhrgebiet, Landgrafenstr. 15, 44652 Herne, Germany. Zochling@rheumazentrum-ruhrgebiet.de

Expert Opinion on Pharmacotherapy
|April 26, 2006
PubMed
Summary

Anti-tumor necrosis factor-alpha (TNFα) therapies have revolutionized rheumatology, significantly improving ankylosing spondylitis management. This review details these advances and their integration into current clinical practice guidelines.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantification of anisotropic biophysical properties of lower leg muscles at passive dorsiflexion and plantarflexion using magnetic resonance elastography and diffusion tensor imaging.

Journal of the mechanical behavior of biomedical materials·2025
Same author

[Methotrexate osteopathy-a critical review].

Zeitschrift fur Rheumatologie·2025
Same author

Intervertebral disc degeneration of the lumbar spine assessed in vivo with 3T magnetic resonance tomoelastography.

Radiology advances·2025
Same author

[Hypermobility-Importance in rheumatology].

Zeitschrift fur Rheumatologie·2025
Same author

Disease activity and mental health symptoms in axial spondyloarthritis: concordant or discordant?

Rheumatology (Oxford, England)·2025
Same author

[Diagnostics and treatment of gout : Short version of the German S3 guideline].

Zeitschrift fur Rheumatologie·2025

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Anti-tumor necrosis factor-alpha (TNFα) therapies represent a major advancement in rheumatology.
  • Ankylosing spondylitis (AS) management has seen remarkable improvements with these agents.

Purpose of the Study:

  • To review treatment advances in ankylosing spondylitis.
  • To outline the incorporation of anti-TNFα agents into clinical recommendations.

Main Methods:

  • Literature review of anti-TNFα therapies in rheumatology.
  • Analysis of evidence- and expertise-based clinical recommendations for AS.

Main Results:

  • Anti-TNFα therapy has dramatically improved patient care in AS.
  • Clinical recommendations are evolving to incorporate these new treatment strategies.

Related Experiment Videos

Conclusions:

  • Anti-TNFα agents are integral to modern ankylosing spondylitis management.
  • Evidence-based guidelines are crucial for optimizing patient care with these therapies.